Overview

A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
This is an exploratory study to assess whether vildagliptin, an unapproved drug, can increase insulin secretion in subjects with pre-diabetes who have a defect in the insulin response and elevated levels of fasting glucose.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Vildagliptin